Celgene All

July 25th 2024

Exploring New Possibilities in Kidney Cancer Detection and Therapy

Multiple confirmed responses in a phase 2 trial support the FDA designation for the experimental therapy in squamous cell carcinoma of the head and neck.

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD

July 22nd 2024

28 Enhancing the Interpretation of Real-World Quality of Life (QoL) in Patients With Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Enrolled in the POLARIS Trial

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Gabrielle Rocque;Joanne L. Blum, MD, PhD;Yan Ji;Eric Gauthier;Yao Wang;Monica Z. Montelongo;Joseph C. Cappelleri;Connie Chen;Meghan S. Karuturi;Debu Tripathy, MD

Overcoming Physical and Social Barriers in the Lymphoma Field

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Julie M. Vose, MD, MBA;Avyakta Kallam, MD

July 15th 2024

FDA Accepts Resubmitted BLA for Remestemcel-L in Pediatric SR-aGVHD

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

The agency has set a Prescription Drug User Fee Act date of January 7, 2025, for its decision on approving remestemcel-L in this patient population.

Russ Conroy

Flexible Monitoring for CAR T-Cell Therapy May Improve Treatment Access

The agency has set a Prescription Drug User Fee Act date of January 7, 2025, for its decision on approving remestemcel-L in this patient population.

Following rare CRS and ICANS incidence following CAR T-cell therapy, investigators propose a reduced 2-week monitoring period with extensions as needed.

Ozuriftamab Vedotin Gains FDA Fast Track Designation for Recurrent SCCHN

Following rare CRS and ICANS incidence following CAR T-cell therapy, investigators propose a reduced 2-week monitoring period with extensions as needed.

Related Content

July 25th 2024

Exploring New Possibilities in Kidney Cancer Detection and Therapy

Multiple confirmed responses in a phase 2 trial support the FDA designation for the experimental therapy in squamous cell carcinoma of the head and neck.

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD

July 22nd 2024

Gabrielle Rocque;Joanne L. Blum, MD, PhD;Yan Ji;Eric Gauthier;Yao Wang;Monica Z. Montelongo;Joseph C. Cappelleri;Connie Chen;Meghan S. Karuturi;Debu Tripathy, MD

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Overcoming Physical and Social Barriers in the Lymphoma Field

Julie M. Vose, MD, MBA;Avyakta Kallam, MD

July 15th 2024

FDA Accepts Resubmitted BLA for Remestemcel-L in Pediatric SR-aGVHD

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Russ Conroy

Flexible Monitoring for CAR T-Cell Therapy May Improve Treatment Access

The agency has set a Prescription Drug User Fee Act date of January 7, 2025, for its decision on approving remestemcel-L in this patient population.